title: Cost and financing issues limit access to the HPV vaccine.
abstract: Cervical cancer is a leading cause of death from cancer among women in low-resource settings, affecting women at a time of life when they are critical to social and economic stability. Every year, about 500,000 women worldwide are diagnosed with cervical cancer and more than 250,000 die from the disease. It is the leading cancer in women in half the countries of the world and mostly affects relatively young poor women. But the vaccine cost is too high. With the availability of cost-effective, safe vaccine, there is real hope for reducing the global burden of cervical cancer.
authors.affiliation: BioSciences Research Institute, AG3, Shanthi colony, Anna nagar, Chennai, India. muthuonco@gmail.com
authors.forename: M
authors.initials: M
authors.lastname: Muthumariappan
authors.forename: G Antony
authors.initials: GA
authors.lastname: Raj
mesh_terms: D003362:Cost-Benefit Analysis; D005260:Female; D006297:Health Services Accessibility / Q000191:economics*; D006801:Humans; D030361:Papillomavirus Infections / Q000191:economics* / Q000517:prevention & control; D053918:Papillomavirus Vaccines / Q000191:economics*; D002583:Uterine Cervical Neoplasms / Q000191:economics* / Q000517:prevention & control
chemical_list: D053918:Papillomavirus Vaccines